MedTrace Logo

Extended ECG Monitoring in HCM Patients

NCT04056715 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-03-01

No results posted yet for this study

Summary

The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc. Zio XT device results in identifying a greater burden of nonsustained ventricular tachyarrhythmia (nsVT) compared to current ACCF/AHA guideline recommended 48-hour monitoring.

Conditions

Interventions

DEVICE

Zio XT

ambulatory cardiac monitoring device

Sponsors & Collaborators

  • iRhythm Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Martin Maron, MD · Tufts Medical Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2022-04-18
Completion
2022-04-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04056715 on ClinicalTrials.gov